← Leaderboards
Willy Hugo
University Of California Los Angeles
$2,296,395
Attributed
$2,296,395
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $477K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,296,395 · 1
By mechanism
R01$2,296,395 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Roger S Lo$11,431,145
- James S. Economou$9,911,213
- Antoni Ribas$28,929,216
- Caius Gabriel Radu$8,088,566
- Elizabeth R Sowell$36,362,090
Others in their field
Other Emerging Leaders on “Anti-Pd-1”
- John Freymann · Leidos Biomedical Research, Inc.$5,261,900
- Tina Garyantes · Linnaeus Therapeutics, Llc$5,000,000
- Amaia Lujambio · Icahn School Of Medicine At Mount Sinai$4,251,878
- Alexander Huang · University Of Pennsylvania$3,639,634
- Yuliya Pylayeva-Gupta · Univ Of North Carolina Chapel Hill$3,602,417
- Jun Wang · New York University School Of Medicine$3,408,076
Research focus
Anti-Pd-1EvolutionAutomobile DrivingAutopsyAnti-Ctla4BiologicalBiologyBiopsyBraf GeneBrainCancer PatientCardiovascular SystemCell CompartmentationCell GrowthCellsCessation Of LifeClinically RelevantClinical TrialsCombination ImmunotherapyDependenceDisease ProgressionDistantEnvironmentFuture
Grant awards (5)
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance$439,813
R01 · FY2024 · CA · contact PI
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance$453,702
R01 · FY2023 · CA · contact PI
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance$462,960
R01 · FY2022 · CA · contact PI
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance$462,960
R01 · FY2021 · CA · contact PI
Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance$476,960
R01 · FY2020 · CA · contact PI